GlassScriptPhysician profile
Yudith Crawford
NPI 1326758962
$3,831.44
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,984 · 2024: $1,560 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,741 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,741.45 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $572.73 | 2023-2024 | Fintepla, Nayzilam, Briviact |
| Abbvie INC. | $419.99 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $303.76 | 2023 | Ingrezza, Ongentys |
| Inspire Medical Systems, INC. | $283.31 | 2023-2024 | Inspire |
| Sk Life Science, INC. | $203.30 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $190.24 | 2023 | |
| Argenx US, INC. | $176.05 | 2023-2025 | Vyvgart Hytrulo |
| Harmony Biosciences LLC | $159.09 | 2024-2025 | |
| Genentech USA, INC. | $149.06 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biogen, INC. | $139.30 | 2023-2024 | Vumerity, Tysabri |
| Emd Serono, INC. | $128.16 | 2023-2024 | Mavenclad |
| Lundbeck LLC | $117.74 | 2023-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $114.07 | 2023-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $109.77 | 2023 | |
| Lilly USA, LLC | $95.37 | 2023-2024 | Emgality, Kisunla, Amyvid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.95 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $83.18 | 2023-2024 | Austedo Xr, Austedo |
| Amneal Pharmaceuticals LLC | $79.16 | 2023-2024 | Rytary, Ongentys |
| Janssen Pharmaceuticals, INC | $62.42 | 2023-2024 | Spravato |
| Ge Healthcare | $56.33 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $43.79 | 2024 | |
| Axsome Therapeutics, INC. | $42.15 | 2024 | Sunosi |
| Kyowa Kirin, INC. | $39.57 | 2023 | Nourianz |
| Acadia Pharmaceuticals INC | $31.12 | 2023 | Daybue |
| Alexion Pharmaceuticals, INC. | $30.38 | 2024 | Ultomiris |
| Avadel Cns Pharmaceuticals, LLC | $26.91 | 2024 | Lumryz |
| Merz Pharmaceuticals, LLC | $22.62 | 2025 | Ampyra, Inbrija, Xeomin |
| Octapharma USA, INC. | $21.20 | 2025 | Panzyga |
| Alnylam Pharmaceuticals INC. | $19.82 | 2023 | Amvuttra |
| Ani Pharmaceuticals, INC. | $17.90 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yudith Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.